Mental disorders
Because mood disorders can hamper recovery from labyrinthitis, treatment may also include any co-occurring anxiety disorder or depression. Severe anxiety episodes are usually addressed by short-term benzodiazepine therapy. Prognosis
Recovery from acute labyrinthine inflammation generally takes from one to six weeks, but it is not uncommon for residual symptoms such as dysequilibrium and dizziness to last for a couple of months.Recovery from a temporary damaged inner ear typically follows two phases:

An acute period, which may include severe vertigo and vomiting
approximately two weeks of sub-acute symptoms and rapid recovery

Epidemiology
Labyrinthitis affects approximately 35 million people per year (approximately 3.5 cases per 100,000 people). It typically occurs in those between 30 and 60 years of age, and there are no significant differences between male and female incidence rates. In 95% of cases, sufferers experience a single attack and fully recover. Vestibular rehabilitation showed a statistically significant increase in controlling symptoms over no intervention in people who have vestibular neuritis. References
External links

Labyrinthitis at Curlie
General anaesthesia with isoflurane reduces plasma endocannabinoid AEA concentrations, and this could be a consequence of stress reduction after loss of consciousness. History
Together with enflurane and halothane, Isoflurane began to replace the flammable ethers used in the pioneer days of surgery; this shift began in the 1940s to the 1950s. Its name comes from being a structural isomer of enflurane, hence they have the same empirical formula. Environment
The average lifetime of isoflurane in the atmosphere is 3.2 years, its global warming potential is 510 and the yearly emissions add up to 880 tons. Veterinary use
Isoflurane is frequently used for veterinary anaesthesia. References
External links
"Isoflurane". Drug Information Portal. U.S. National Library of Medicine. U.S. Patent 3,535,388 - 1-chloro-2,2,2-trifluoroethyl difluoromethyl ether
U.S. Patent 3,535,425 - 1-chloro-2,2,2-trifluoroethyl difluoromethyl ether as an anesthetic agent